Search Results

tissues like tumors slows offset and improves therapeutic window ✅ Examples of how rebinding in dense receptor Diffusion, Rebinding, and Receptor Density: The In Vivo Edge This lecture shows how tissue architecture And when receptors are dense (like GPCRs on membranes), this rebinding hits the collisional limit , where Subscribe to The Kenakin Brief today ➤ #TargetResidenceTime #DrugBindingKinetics #PKPDdissociation #ReceptorPharmacology

September 2022 "The Smoothened receptor (SMO, a 7 pass transmembrane domain, Class F GPCR family protein In the absence of HH signaling, SMO is inhibited by Patched 1 (PTC1; a 12 pass transmembrane domain protein

September 2022 "In the Wnt-β-catenin pathway, Wnt binding to Frizzled (Fzd) and LRP5 or LRP6 (LRP5/6) co-receptors Using purified Fzd proteins reconstituted in lipid nanodiscs, we investigated the factors that promote

Could they map receptor heterogeneity across the islet? Could they quantify plasma membrane vs. intracellular receptor pools? The tools didn’t simply visualize receptors. mapping Super-resolution imaging of receptor nanodomains AI-assisted probe design Multi-receptor visualization Not one receptor at a time. Not one color. Not one imaging depth.

GPCR Activation and Signaling The GPCR adaptor protein Norbin regulates S1PR1 trafficking and the morphology , cell cycle and survival of PC12 cells GLP-1 and GIP receptors signal through distinct β-arrestin 2- mobilization when combined with propranolol Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor

The cannabinoid receptor type 2 (CB2R) has emerged as a compelling target across inflammation, immune Subcellular membrane mixtures, altered receptor conformations, and non-specific interactions introduce By quantifying ligand–receptor interactions directly in intact cells, HCS allows researchers to observe In a recent collaborative study, 16 synthetic cannabinoid receptor agonists (SCRAs) were evaluated using Because imaging is captured across thousands of intact cells, each measurement incorporates receptor

Screening Compounds are systematically challenged in vitro against a spectrum of cellular targets—enzymes, receptors safety Reactive Metabolites and Irreversible Damage Formation of reactive metabolites that alkylate proteins

Watch Episode 167 Some GPCR-targeting antibodies don’t inhibit receptors. They activate them. Tom Sakmar points to a largely overlooked mechanism  in disease: autoantibodies that don’t block receptors “Some of these antibodies actually activate the receptor and cause pathological signaling.” — Tom Sakmar Luminex assay , researchers can now: Screen patient samples for GPCR autoantibodies Identify which receptor

drugs fail—not because of poor chemistry, but because we’ve misunderstood how these shape-shifting proteins

Kunitz-type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor from the Dendroaspis angusticeps venom is the most selective antagonist of the arginine-vasopressin V2 receptor

The goal is to accelerate receptor-targeted discovery. It highlights its journey from one receptor to a cross-family toolkit. Hear from Drs. GPR45 steps up: A previously orphan receptor emerges as a powerful target for appetite and obesity control

Think a drug just "locks into" a receptor and does its job? Think again. It explains how the concentration of a drug influences its binding to the receptor. Instead, it involves a dynamic interaction between the drug and the receptor. The receptor may change shape upon binding, affecting how the drug interacts and how effective it will Understanding the intricate details of drug-receptor interactions transforms how we approach pharmacology

Most drugs don’t fail at the receptor level—they fail before they even reach it. In every lab, candidates fail not because they lack potency at a receptor, but because they stumble at Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives Even the most elegant GPCR ligand can fail if it never reaches its receptor. You’re not just designing for receptor activity—you’re designing for enzyme survival.

Picture this: two compounds bind to the same receptor. One sparks a firestorm of cellular activity. Terry walks you through real-world experiments, decades of receptor pharmacology wisdom, and the cutting-edge

Celtarys Research expands its assay tools with CELT-419 for D3 receptor studies, and Dr. Terry Kenakin brings translational clarity to complex receptor concepts.   Platforms   Celtarys Research presents CELT-419, a nanomolar-affinity fluorescent ligand optimized for D3 receptor Highlights     Phosphorylation selectively regulates β-arrestin recruitment  across glucagon family receptors

University of Michigan, walks us through how positive allosteric modulators (PAMs) targeting the mu-opioid receptor That’s huge.” – Ben Clements By combining chronic pain models with receptor-level pharmacology, Ben Allosteric modulation is already proven in ion channels (think benzodiazepines and barbiturates) but University today. _______________ Keyword Cloud: GPCR research community, GPCR drug discovery, mu-opioid receptor

Fast-forward a few thousand years, and we’re talking beta receptors, receptor theory, and AI-generated

correlation network analysis (WGCNA) were performed using R software, and functional enrichment analysis and protein–protein

will focus on the application of artificial intelligence (AI), machine learning, and the design of protein of Oxford, where she is currently Professor of Structural Bioinformatics and leads the University’s Protein

For GPCR-focused programs, the ability to visualize receptor localization, internalization kinetics, The resulting multiparametric datasets are well-suited for GPCR research, where receptor trafficking, For GPCR assay developers, HCS supports:  Quantitative visualization of receptor internalization and Their ability to visualize ligand–receptor interactions directly in living cells produces data that are advantages include: Physiological Relevance Fluorescent ligand binding occurs in intact cells, preserving receptor

47th Symposium on Hormones & Cell Regulation; new approach to GPCR internalization analysis; “Soluble Proteins Target protected agonism:  Internalized MT2 signaling escapes AGRP antagonism—unlike α-MSH. Dual-label specificity blocks promiscuous ligand confusion Lanthanide donors + d2 acceptors = high SNR

It will bridge foundational receptor theory with today’s most pressing pharmacological questions, from Kenakin   Four decades of receptor theory now fit in one expert-guided hub.

He’s focused on RGS proteins , pain comorbidities  like addiction and depression, and pushing for more

ATP and sugar monophosphates and the identification of a novel allosteric site on the vasopressin V2 receptor Discover how factors like restricted tissue diffusion and receptor density can dramatically alter drug Learn how fentanyl slows inhalation via opioid receptors, while xylazine prolongs exhalation through alpha-2 adrenergic receptors, creating a synergistic effect that drives overdose deaths.

In this session, you’ll gain: ✅ A clear breakdown of how intracellular vs. extracellular receptor access In this protected environment, pharmacokinetics can decouple from plasma clearance. GPCRs Aren’t Just Surface Receptors Anymore From β2-adrenoreceptors to CCRs and dopamine receptors, multiple

Depending on which ligand activates a receptor, it can engage different intracellular transducers. 'biased signalling' paradigm requires that we now characterize physiological signalling not just by receptors but by ligand-receptor pairs. The guidelines will aid consistency and clarity, as the basic receptor research and drug discovery communities

Revered for its convenience, the FLIPR assay provides rapid insights into receptor activity.

trisphosphate, which are downstream signal transducers for the expression of fetal genes, increased protein

Abs against the angiotensin II receptor subtype 1 (AT1R) and the endothelin receptor type A (ETAR) are Promising nuclear receptors as key regulators of transcriptional programmes will be introduced as well

Reading those first papers on GPCR signaling organization absolutely fascinated me — the idea that receptors to integrated signaling landscapes, accelerating drug discovery timelines and expanding targetable receptor